Modality
Bispecific Ab
MOA
CAR-T BCMA
Target
EGFR
Pathway
DDR
FSGSCholangiocarcinomaEndometrial Ca
Development Pipeline
Preclinical
~Oct 2010
→ ~Jan 2012
Phase 1
~Apr 2012
→ ~Jul 2013
Phase 2
~Oct 2013
→ ~Jan 2015
Phase 3
~Apr 2015
→ ~Jul 2016
NDA/BLA
~Oct 2016
→ ~Jan 2018
Approved
Apr 2018
→ Jun 2029
ApprovedCurrent
NCT03126443
2,419 pts·FSGS
2023-07→2029-06·Terminated
NCT08191036
1,096 pts·Endometrial Ca
2023-10→2025-03·Completed
NCT07931551
1,437 pts·FSGS
2018-04→2026-01·Not yet recruiting
4,952 total pts2 indications
CompletedCurrentUpcoming
Catalysts (3)
2025-03-021.1y agoPh3 Readout· Endometrial Ca
2026-01-272mo agoPh3 Readout· FSGS
2029-06-203.2y awayPh3 Readout· FSGS
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
Approved
Not yet…
Approved
Termina…
Approved
Complet…
Catalysts
Ph3 Readout
2025-03-02 · 1.1y ago
Endometrial Ca
Ph3 Readout
2026-01-27 · 2mo ago
FSGS
Ph3 Readout
2029-06-20 · 3.2y away
FSGS
CompletedTerminatedNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03126443 | Approved | FSGS | Terminated | 2419 | HAM-D |
| NCT08191036 | Approved | Endometrial Ca | Completed | 1096 | 6MWD |
| NCT07931551 | Approved | FSGS | Not yet recr... | 1437 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| Zanurapivir | Neurocrine | NDA/BLA | EGFR | |
| JAZ-8729 | Jazz Pharma | Phase 2/3 | FcRn | |
| ACA-2691 | Acadia Pharma | Phase 3 | BCMA | |
| RCU-2903 | Arcus Bio | NDA/BLA | EGFR |